Wake Forest University Health Sciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).

1,140 total trials 174 currently recruiting 724 completed early-phase tilt top decile by trial count

Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.

Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.

Top-decile sponsor footprint

Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,140 total, page 11 of 23

COMPLETED Phase 3

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

NCT05967442

TERMINATED Early Phase 1

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

NCT03870529

COMPLETED NA

Virtual Behavioral Health Integration

NCT04106388

COMPLETED Phase 4

Effects of Intramuscular Oxytocin on Sensory Function in Healthy Volunteers With Ultraviolet Burn Injury to the Skin

NCT03935399

COMPLETED NA

Reducing the Experience of Menopausal Symptoms Through Temperature

NCT03937466

COMPLETED NA

In Office Versus Telemedicine Preoperative Visit

NCT04023175

COMPLETED Phase 4

The Effect of Brimonidine

NCT03959176

COMPLETED

Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer

NCT03963739

COMPLETED NA

Connect Oncology Needs Evaluation Tool

NCT03919864

COMPLETED NA

Implementation of Nurse-guided Web-based Cognitive Behavioral Therapy for Pain Management

NCT03927846

TERMINATED

Palliative Radiation Oncology Chief's Clinic

NCT03995927

COMPLETED Phase 2

Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT

NCT03861091

COMPLETED Phase 4

No Drop Post-Op Cataract Surgery

NCT03864133

COMPLETED Phase 3

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

NCT03867175

COMPLETED NA

Substudy of Protocol NCT03843957 - Effect of mPATH on Screening for Depression, Fall Risk, and Safety

NCT05110014

COMPLETED NA

The Effects of MAP and EtCO2 on Venous Sinus Pressures

NCT03867461

COMPLETED Phase 3

A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease

NCT03740048

COMPLETED NA

Prefistula Forearm Exercise in Pts Requiring Chronic HD Therapy

NCT03988270

COMPLETED NA

Real-time Location System Feasibility Study

NCT03988751

COMPLETED NA

Volunteering as an Intervention to Reduce Depression Among Adolescents

NCT03816215

COMPLETED Phase 1

The Effects of Sedatives on Tobacco Use Disorder

NCT03813121

COMPLETED

Social Determinants of Health in Glioblastoma Population

NCT03900689

TERMINATED

Medical Data Collection in the Formation of Precision Oncology Registry

NCT03874065

COMPLETED Phase 1

The Interaction Between Diabetes and Estradiol on Human Brain Metabolism in Postmenopausal Women

NCT03681691

COMPLETED Phase 4

PK Sampling After IV Oxytocin and Effects on Sensory Function in Healthy Volunteers

NCT03929367

COMPLETED NA

Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

NCT03696797

COMPLETED

Carolinas Cardiogenic Shock Initiative

NCT04985708

COMPLETED Phase 2

Study of Nasal Insulin to Fight Forgetfulness - Device Study

NCT03857321

COMPLETED

Effect of Opioid Shortage on Drug Selection

NCT04099030

COMPLETED

Airway Deadspace in Children: Air-Q Versus Endotracheal Tube

NCT03785977

COMPLETED Phase 2

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

NCT03475186

TERMINATED Early Phase 1

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

NCT03796273

COMPLETED Early Phase 1

Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels

NCT03747523

COMPLETED NA

Lumbar Plexus Block Versus Quadratus Lumborum Block for Primary Anterior Total Hip Arthroplasty

NCT03409900

TERMINATED NA

Secondary Versus Tertiary Wound Closure in High Risk Gynecologic Abdominal Surgical Incisions

NCT03861065

COMPLETED NA

Assessing Patient Anxiety During Mohs Micrographic Surgery

NCT03756792

TERMINATED

Epigenetic and Metabolomic Changes in Childhood Cancer Survivors

NCT03866707

COMPLETED

The Impact of Cytochrome P450 Abnormalities in Patients With Delirium.

NCT03829670

TERMINATED

Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone

NCT03529565

COMPLETED NA

Improving Morbidity During Post-Acute Care Transitions for Sepsis

NCT03865602

COMPLETED Phase 2

Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy

NCT03496805

COMPLETED

The Endocannabinoid System in Human Gestational Tissues in Labor

NCT03752021

COMPLETED NA

Development of Fluid Intake App for Management of Fluid Intake During Hemodialysis

NCT03759847

TERMINATED Phase 2

Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

NCT03152786

TERMINATED Early Phase 1

Liposomal Bupivacaine (Exparel) in Sarcomas

NCT03867188

COMPLETED NA

LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)

NCT03593395

TERMINATED NA

Comparison of Fluid Capture Efficiency of the Total Capture Drape Versus a Standard Drape for Hysteroscopy

NCT04540952

COMPLETED NA

U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk

NCT03688126

COMPLETED Phase 1

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

NCT03773107

COMPLETED Phase 2

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03188432

← Previous Page 11 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 96
Phase 2 143
Phase 3 31
Phase 4 80

What is open in the Wake Forest University Health Sciences pipeline

174 recruiting of 1,140 indexed (15% open); 724 completed (64%).

Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wake Forest University Health Sciences: open-pipeline peers nationwide

Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share Wake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthUniversity of North Carolina, Chapel HillUniversity of FloridaBaylor UniversityCornell UniversityArrowhead Regional Medical CenterAurinia Pharmaceuticals
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,140 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Wake Forest University Health Sciences page

1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.

  • 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.